J&J, ViiV's two-drug regimen meets in Phase III for maintenance treatment of HIV-1 infection

ViiV Healthcare Ltd. (Brentford, U.K.) and Johnson & Johnson (NYSE:JNJ) said a two-drug regimen comprising cabotegravir and Edurant rilpivirine met the primary endpoint in the Phase III ATLAS trial as maintenance treatment in HIV-1-infected adults who are virologically suppressed.

On the primary endpoint, switching to cabotegravir plus Edurant was non-inferior to continuing standard of care (SOC) with a once-daily oral three-drug regimen in the proportion of patients with plasma HIV-1 RNA levels of ≥50 copies per mL at week 48...